New approaches to the understanding of tamoxifen action and resistance

Endocrine-Related Cancer

Volumn 10, Issue 2, 2003, Pages 267-277

  Berstein, L M ^a,b   Zheng, H ^a   Yue, W ^a   Wang, J P ^a   Lykkesfeldt, A E ^c   Naftolin, F ^d   Harada, N ^e   Shanabrough, M ^d   Santen, R J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c Institute of Cancer Biology   (Denmark)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE; ESTRADIOL; ESTROGEN; FARNESYLTHIOSALICYLIC ACID; GUANOSINE TRIPHOSPHATE; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN;

BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG ELIMINATION; ESTROGEN METABOLISM; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FARNESOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NITRILES; RECEPTORS, ESTROGEN; SALICYLIC ACIDS; TAMOXIFEN; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 0037903066     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100267     Document Type: Conference Paper

References (35)

1. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH & Murphy LC 2002 Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clinical Cancer Research 8 1747-1753.
2. Ali S & Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer 2 101-112.
3. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F & Reddy KB 2002 MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21 4000-4008.
4. Berstein LM, Yue W, Zheng H, Wang J-P, Lykkesfeldt AE & Santen RJ 2002 Aromatase and MAPK activity in MCF-7 cells treated long-term with tamoxifen and in tamoxifen-resistant MCF-7 cells. Proceedings of the 84th Annual Meeting of the Endocrine Society (USA) P1-659.
5. Clarke R, Leonessa F, Welch JN & Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacology Reviews 53 25-71.
6. Kip1 deregulation and antiestrogen resistance in human breast cancer cells. Journal of Biological Chemistry 276 40888-40895.
7. Dorssers LCJ, van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EMJJ, Klijn JGM, Beex LVAM & Foekens JA 2001 Tamoxifen resistance in breast cancer. Elucidating mechanisms. Drugs 61 1721-1733.
8. Dowsett M, Macaulay V, Gledhill J, Ryde C, Nicholls J, Answorth A, McKinna JA & Smith IE 1993 Control of aromatase in breast cancer cells and its importance for tumor growth. Journal of Steroid Biochemistry and Molecular Biology 44 605-609.
9. Duh JL, Yu R, Jiao JJ, Matwyshyn GA, Li W, Tan TH & Kong AN 1997 Activation of signal transduction kinases by tamoxifen. Pharmaceutical Research 14 186-189.
10. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N & Constantino J 1996 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors. Journal of the National Cancer Institute 88 1529-1542.
11. Gee JM, Robertson JFR, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247-254.
12. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
13. Gray R 1993 Tamoxifen: how boldly to go where no women have gone before. Journal of the National Cancer Institute 85 1358-1360.
14. Horwitz KB 1995 Editorial: when tamoxifen turns bad. Endocrinology 136 821-823.
15. Jeng M-H, Yue W, Eischeid A, Wang J-P & Santen RJ 2000 Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 62 167-175.
16. Johnston SR 1997 Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 8 911-930.
17. Katzenellenbogen BS, Montano M, Ekena K, Herman ME & McInerney EM 1997 Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Research and Treatment 44 23-38.
18. Kloog Y & Cox AD 2000 RAS inhibitors: potential for cancer therapeutics. Molecular Medicine Today 6 398-402.
19. Lykkesfeldt A & Briand P 1986 Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. British Journal of Cancer 53 29-35.
20. MacGregor JI & Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacology Reviews 50 151-196.
21. Madsen MW, Reiter BE, Larsen SS, Briand P & Lykkesfeldt AE 1997 Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Research 57 585-589.
22. Mandell JW, Hussani IM, Zecevic M, Weber M & Vanden Berg SR 1998 In situ visualization of intratumor growth factor signaling. American Journal of Pathology 153 1411-1423.
23. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y & Kloog Y 1995 Selective inhibition of Ras-dependent cell growth by farnesylthiosalicylic acid. Journal of Biological Chemistry 270 22263-22270.
24. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
25. Miller WR & Mullen P 1993 Factors influencing aromatase activity in the breast. Journal of Steroid Biochemistry and Molecular Biology 44 597-604.
26. Osborne CK, Coronado EB & Robinson JP 1987 Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer 23 1189-1196.
27. Rabenoelina F, Semlali A, Duchesne M-J, Freiss G, Pons M & Badia E 2002 Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. International Journal of Cancer 98 698-706.
28. Santen RJ 1996 Long term tamoxifen therapy: can an antagonist become an agonist? Journal of Clinical Endocrinology and Metabolism 81 2027-2029.
29. Santen RJ & Harvey HA 1999 Use of aromatase inhibitors in breast carcinoma. Endocrine Related-Cancer 6 75-92.
30. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafel L, Zaino R & Santner S 1994 Stromal spindle cells contain aromatase in human breast tumors. Journal of Clinical Endocrinology and Metabolism 79 627-632.
31. Santen RJ, Jeng M-H, Wang J-P, Song R, Masamura S, McPherson R, Santner S, Yue W & Shim W-S 2001 Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 79 115-125.
32. Shim W-S, Conaway M, Masamura S, Yue W, Wang J-P & Santen RJ 2000 Estradiol hypersensitivity and MAP kinase expression in long term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396-405.
33. Shozu M, Sumitani H, Murakami K, Segawa T, Yang HJ & Inoue M 2001 Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase. Journal of Steroid Biochemistry and Molecular Biology 79 61-65.
34. Yue W, Santen RJ, Wang J-P, Hamilton CJ & Demers LM 1999 Aromatase within the breast. Endocrine-Related Cancer 6 157-164.
35. Zhang Z, Maier B, Santen RJ & Song RX 2002 Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochemical and Biophysical Research Communications 294 926-933.